G&S Capital’s Insys Therapeutics, Inc. INSY Stock Holding History

G&S Capital’s Portfolio INSY Stock Details INSY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-400	Closed	-$1K	–	251
2018 Q4	$1K	Hold	400	–	–	﹤0.01%	209
2018 Q3	$4K	Hold	400	–	–	﹤0.01%	192
2018 Q2	$3K	Hold	400	–	–	﹤0.01%	191
2018 Q1	$2K	Buy	+400	New	+$3.3K	﹤0.01%	185

Other funds holding INSY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

G&S Capital's INSY Position: Q1 2019 in Review

G&S Capital sold out of Insys Therapeutics, Inc. (INSY) in Q1 2019, closing a stake of 400 shares — an estimated $1K sold.

G&S Capital first reported a position in INSY in Q1 2018 and held it in 4 quarters. The position peaked at $4K in Q3 2018. 98 funds tracked by Wall St. Rank hold INSY as of Q1 2019.

G&S Capital reported no remaining Insys Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
G&S Capital sold 400 Insys Therapeutics, Inc. shares in Q1 2019, an estimated $1K.
G&S Capital first reported a position in Insys Therapeutics, Inc. in Q1 2018 and held it in 4 quarters.
G&S Capital's Insys Therapeutics, Inc. position peaked at $4K in Q3 2018.
98 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2019.

Based on G&S Capital's 13F filing for Q1 2019, filed 22 Apr 2019.